States’ Limits On OTC Dextromethorphan Sales Could Force Congress’ Hand
This article was originally published in The Pink Sheet
US House legislation banning the sale of DXM OTCs to consumers under age 18 likely stands the same chance right now as previous versions that have failed, but CHPA expects an increasing number of state laws could spur future action.
You may also be interested in...
DXM age-restriction bill in Senate; Mosquito band marketer settles with FTC; and more news in brief.
Florida is the first of several states CHPA expects in 2016 will pass legislation banning sales of DXM-containing OTCs to minors. CHPA looks this year to support similar bills in Arkansas, Pennsylvania and Ohio while keeping an eye toward state activity on sales of PSE-containing OTCs.
An HHS agency’s 2013 drug use survey shows the number of meth users rising by 155,000 after changing little the previous two years. Acura Pharmaceuticals notes the survey and Tennessee data showing that making only tamper-resistant, single-ingredient PSE products available affects the diversion rate.